ENCOURAGING DATA FROM MALARIA STUDY PRESENTED
- Category: Vaccines
- Published on Monday, 12 April 2010 03:00
- Hits: 1031
GenVec announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium—Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11–16, 2010 in Copper Mountain, Colorado
GAITHERSBURG, MD, USA | April 12, 2010 | GenVec, Inc. (Nasdaq: GNVC) announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium—Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11–16, 2010 in Copper Mountain, Colorado.
Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a malaria trial using GenVec technology were presented. Data indicate malaria vaccines given to malaria-naïve adults were found to be safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions. Sterile protection, a complete absence of parasites in the blood, was seen in 4 out of 15 volunteers that had been inoculated with the vaccine and subsequently challenged with the malaria parasite.
This clinical trial is being conducted under sponsorship from the United States Army Medical Materiel Development Activity (USAMMDA) and with financial support from the U.S. Agency for International Development, the Congressionally Directed Peer Review Medical Program, and the Military Infectious Diseases Research Program. “The results of this study are encouraging and we are looking forward to gaining more insight regarding the potential for this vaccine,” stated Dr. Douglas Brough, GenVec’s Vice President of Research.
Malaria is one of the world’s leading lethal infectious diseases. Malaria is a lifethreatening disease transmitted to humans through the bite of an infected mosquito. Malaria parasites initially invade liver cells and, after multiplying, release tens of thousands of new parasites, which invade red blood cells, multiply again, and then destroy these cells. High fever, headache, and vomiting appear approximately nine to fourteen days after the infectious bite. If untreated, the infection can progress rapidly and become life threatening—destroying red blood cells, causing severe anemia, and blocking 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com capillaries that carry blood to the brain, resulting in coma and/or death. Malaria causes approximately 243 million acute illnesses and 863,000 deaths annually, mostly among children under the age of five. Malaria is a major health risk for travelers and the military.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the Company’s various filings with the Securities and Exchange Commission.
SOURCE: GenVec, Inc.